Company intelligence / Profile preview

4Moving Biotech

Ownership: Private
Development stage: Phase 2

Overview

4Moving Biotech has completed a Phase 1 study evaluating the safety and tolerability of 4P004 in osteoarthritis patients. The company is now conducting a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial called INFLAM MOTION across the EU, US, and Canada to evaluate the efficacy of 4P004 in individuals with knee osteoarthritis. The trial will enroll 129 patients and is expected to have the first patient enrolled in the second quarter of 2025.[5][6]

Therapeutic areas: Rheumatology
Modalities: GLP-1 analogPeptide
Industry: Biotech

Drug pipeline

1 asset

4P004v

Unknown

Beyond the preview

Go deeper on 4Moving Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4Moving Biotech.

Explore the full profile